🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Another very important message! May 20th update…. #rc4ms youtube.com/shorts/L4vUAA9…

Montel Williams: Multiple Sclerosis, and Opioid Addiction youtu.be/l2BZd0hdPEk?si… via Dr. Brandon Beaber

This interesting article reports the co-occurrence of Down Syndrome and multiple sclerosis is much lower than would be expected and speculates there could be a protective effect of amyloid precursor protein (APP) and S100 calcium-binding protein B (S100B) jstage.jst.go.jp/article/ejmj/7…

Good morning

realtalkms.com/403 Dr. Bruce Bebo shares how a new framework for describing MS can help facilitate the development of targeted, personalized treatment. We’re talking about it on RealTalk MS. #MultipleSclerosis nahla siddig #MSEndsWithUs

The "Gate" Theory of Neuropathic Pain youtube.com/shorts/PFw-7LC…

realtalkms.com/403 Dr. Daniel Ontanda offers his insights on how employing more precise language to describe MS can create positive outcomes for those living with MS on RealTalk MS. #MultipleSclerosis

Risk of multiple sclerosis in those who migrated to Ontario, Canada from various countries (compared to those who migrated from the UK). Risk is lowest in Chinese migrants and highest in Iranian migrants pmc.ncbi.nlm.nih.gov/articles/PMC69…

Are doctors missing early signs of pediatric multiple sclerosis. In this study, children subsequently diagnosed with MS had years of increased medical care utilization. pubmed.ncbi.nlm.nih.gov/40407117/

rituximab vs. mavenclad for multiple sclerosis. This retrospective observational study found MRI activity was much lower in those receiving rituximab (17% vs 57% over a median follow up of 4.5 years), but side effects more common with rituximab pubmed.ncbi.nlm.nih.gov/40415655/

The Cause of Autoimmune Disease youtu.be/eUpLdRmteiA?si…

Great to see Dr. Eoin Flanagan leading a session about #MOGAD at #CMSC2025 🧠

Accelerated approval of neurology drugs is under scrutiny such as controversial FDA approvals of aducanumab (Aduhelm) and eteplirsen (Exondys 51). Do you favor accelerated approval or a strict requirement of class Ia evidence? journals.lww.com/neurotodayonli…

Just over here fighting multiple sclerosis one wobbly step at a time.⭐️ #WorldMSDay

MS MRI Lesions vs. "benign" White Matter Lesions youtube.com/shorts/XXZS2Z3…

Results from the FENopta randomized trial (fenebrutinib) open label extension over 96 weeks. Relapse rate per person per year (ARR) was 0.06. The rate of new/enlarging T2 lesions was 0.34 per year pmlive.com/pharma_news/ro…

Does ocrevus work in pediatric MS? This case series (n= 24) showed low rates of relapses (0.08 per person per year). Disability as measured by EDSS stabilized in 75% and improved in 16.7% pubmed.ncbi.nlm.nih.gov/40435665/

A 39 year old woman with multiple sclerosis came to the emergency room with fatigue, nausea, fever, leg tremors, and frequent urination. Laboratory testing showed THIS. What happened?

Beware of low antibodies as a complication of b-cell depleters. This is a case report of a 34 year old man on ocrevus for MS who developed catatonia and fever. MRI showed symmetrical thalamic lesions. He had enterovirus encephalitis. IgG was 4.92 g/L neurology.org/doi/10.1212/WN…

GOOD MORNING!!!